ChromaCode, Inc, a California-based company redefining molecular testing through data science, announced that it has raised a $10 million Series C extension with an investment from Adjuvant Capital. The Adjuvant investment brings the company’s total Series C funding to $38 million. Managing Partner Jenny Yip will join ChromaCode’s Board of Directors. Existing investors Northpond Ventures,…
SpeeDx. Pty Ltd, the developer of innovative clinical diagnostics to support improved patient outcomes, announced it has raised $15 million in additional series B equity investment from U.S.-based Northpond Ventures. “SpeeDx’s molecular diagnostic solutions are having a profound global impact in the areas of STIs, antibiotic resistance markers, and respiratory diseases,” said Michael P. Rubin,…